RNA interference (RNAi) is a natural mechanism regulating protein expression that is mediated by small interfering RNAs (siRNA). Harnessing RNAi has potential to treat human disease; however, clinical evidence for the effectiveness of this therapeutic approach is lacking. ALN-RSV01 is an siRNA directed against the mRNA of the respiratory syncytial virus (RSV) nucleocapsid (N) protein and has substantial antiviral activity in a murine model of RSV infection. We tested the antiviral activity of ALN-RSV01 in adults experimentally infected with wild-type RSV. Eighty-eight healthy subjects were enrolled into a randomized, double-blind, placebocontrolled trial. A nasal spray of ALN-RSV01 or saline placebo was administered daily for 2 days before and for 3 days after RSV inoculation. RSV was measured serially in nasal washes using several different viral assays. Intranasal ALN-RSV01 was well tolerated, exhibiting a safety profile similar to saline placebo. The proportion of culture-defined RSV infections was 71.4 and 44.2% in placebo and ALN-RSV01 recipients, respectively (P = 0.009), representing a 38% decrease in the number of infected and a 95% increase in the number of uninfected subjects. The acquisition of infection over time was significantly lower in ALN-RSV01 recipients (P = 0.007 and P = 0.03, viral culture and PCR, respectively). Multiple logistic regression analysis showed that the ALN-RSV01 antiviral effect was independent of other factors, including preexisting RSV antibody and intranasal proinflammatory cytokine concentrations. ALN-RSV01 has significant antiviral activity against human RSV infection, thus establishing a unique proof-of-concept for an RNAi therapeutic in humans and providing the basis for further evaluation in naturally infected children and adults.antiviral | RNA interference | small interfering RNA | RSV R NA interference (RNAi) is a highly conserved natural cellular mechanism of posttranscriptional regulation observed in eukaryotic cell types (1), including mammalian cells (2, 3). Specifically, RNAi is mediated through the RNA-induced silencing complex (RISC) and involves the targeted cleavage of messenger RNA by the complementary, antisense strand of a double-stranded, small interfering RNA (siRNA) resulting in suppressed expression of the corresponding protein. The discovery of RNAi raises the possibility that this cellular pathway can be harnessed as a unique approach to treat human disease. This possibility has been underscored recently by many in vivo studies of RNAi as treatment in a wide range of animal models of disease, including hypercholesterolemia (4, 5), viral hepatitis (6), Huntington's disease (7,8), and cancers (9). However, definitive evidence is lacking from well-controlled studies for the effectiveness of an RNAi therapeutic against any human disease.Respiratory syncytial virus (RSV) is the most common cause of infant hospitalization in the United States, producing ≈10-fold higher mortality rates than influenza in this population (10). RSV also produces significant m...